Toth Financial Advisory Corp Nektar Therapeutics Transaction History

Toth Financial Advisory Corp

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Jan 22, 2019	SELL	$30.43 - $56.65 $912 - $1,699	-30 Closed	0 $0
Q3 2018 Oct 15, 2018	SELL	$46.46 - $68.49 $696 - $1,027	-15 Reduced 33.33%	30 $2,000
Q2 2018 Jul 23, 2018	BUY	$46.25 - $104.45 $2,081 - $4,700	45 New	45 $2,000

126

109M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $259M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Toth Financial Advisory Corp, based on Form 13F filings with the SEC.

Stay updated on Toth Financial Advisory Corp with notifications on news.